Osteoarthritis Label Should Reflect Clinical Data For Broader Claims- PhRMA
Executive Summary
Osteoarthritis drug labeling should reflect results of specific clinical trials instead of a predetermined pain/function claim structure so that drugs obtain the broadest possible claim, the Pharmaceutical Research & Manufacturers of America suggested in April 20 comments on FDA's draft guidance on "Clinical Development Programs for Drugs, Devices and Biological Products Intended for the Treatment of Osteoarthritis."